ASX 200 healthcare stock tumbles amid $200 million US acquisition

The ASX 200 healthcare company is acquiring a US medical technology business.

| More on:
Health professional looking at a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare stock Sonic Healthcare Ltd (ASX: SHL) is taking a tumble today.

Shares in the global pathology provider closed yesterday trading for $30.50. At the time of writing on Thursday, shares are swapping hands for $29.09 apiece, down 4.6%.

That sees the healthcare share underperforming the ASX 200 today, with the benchmark index down 0.5% at this same time.

This comes following news of a United States-based medical acquisition.

What medical asset is the ASX 200 healthcare stock acquiring?

The Sonic Healthcare share price is dipping after the ASX 200 healthcare stock reported that it has signed binding agreements to acquire Pathology Watch.

Located in the US state of Utah, the medical technology business has developed and commercialised an integrated, end-to-end digital pathology platform for skin pathology.

Sonic will pay US$130 million (AU$200 million) for business, which it will fund from existing cash and debt facilities. Management said it does not consider the transaction to be material for Sonic Healthcare.

Management noted that Pathology Watch is currently at pre-profit stage. However, they expect to "achieve attractive earnings per share and return on invested capital accretion" over the coming years.

The ASX 200 healthcare stock said the opportunities include accelerating Sonic's transition to digital pathology; providing a competitive advantage in existing dermatopathology markets; and promoting "significant synergies" with its AI partner, Franklin.ai.

Commenting on the acquisition, Sonic CEO Colin Goldschmidt said:

The acquisition of Pathology Watch is an important and enormously exciting step in Sonic's transition to digital pathology and pathology AI and offers multiple avenues for value creation.

He added that the next steps are to work with Pathology Watch to "enhance our digital pathology and AI strategy, and to provide competitive advantage for Sonic through a superior service offering to referring physicians and their patients".

The founders, management team and staff of Pathology Watch are expected to stay on with the business.

The acquisition remains subject to customary conditions. Sonic expects to close the transaction in December.

Sonic Healthcare share price snapshot

Today's fall has pushed the ASX 200 healthcare stock back into the red for 2023.

Since the opening bell on 3 January, the Sonic Healthcare share price is now down 1%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.
Healthcare Shares

How much do you need to invest in CSL shares for $8,000 in annual dividends?

CSL's dividends are exponentially more valuable for long-term investors.

Read more »

smiling health care workers in a medical setting
Healthcare Shares

'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stock

This healthcare stock has been given a boost from the US FDA today.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

Why this ASX 200 stock is a retiree's dream

I think this is a very healthy and resilient stock.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Healthcare Shares

Why are so many top fundies overweight on CSL shares?

This is a healthy opportunity, according to a number of fund managers.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Share Fallers

Why did this ASX All Ords stock just crash 16%?

Investors are punishing this ASX All Ords stock on Thursday. But why?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Healthcare Shares

Why two brokers have named this ASX 200 stock as a best buy

Investors may want to pounce on this high-quality stock before it's too late.

Read more »